Clinical evaluation of a new measles-mumps-rubella trivalent vaccine.
In a series of clinical studies of a combined measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) vaccine, 1,481 children received the vaccine or a placebo. The vaccine did not cause any significant reactions. The frequencies of mild, transient fever or rash or both in triple-susceptible vaccinees were similar to those that follow use of Schwarz strain measles vaccine alone. Measles, mumps, and rubella seroconversion rates in triple-susceptible vaccinees ranged from 95% to 100%. Geometric mean antibody titers were as high as those that usually result from use of these same virus strains as monovalent vaccines.
D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D003875:Drug Eruptions / Q000209:etiology; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D007114:Immunization; D007223:Infant; D008297:Male; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D009108:Mumps Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D010919:Placebos; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000009:adverse effects
D000914:Antibodies, Viral; D008458:Measles Vaccine; D009108:Mumps Vaccine; D010919:Placebos; D012411:Rubella Vaccine